Innoviva Specialty Therapeutics Products Reach Galien Final
WALTHAM, Mass., August 11, 2026 Innoviva Specialty Therapeutics (IST) announced that three of its infectious disease therapies, XACDURO® (sulbactam/durlobactam),...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
WALTHAM, Mass., August 11, 2026 Innoviva Specialty Therapeutics (IST) announced that three of its infectious disease therapies, XACDURO® (sulbactam/durlobactam),...
WALTHAM, Mass., June 16, 2026 Innoviva Specialty Therapeutics announced an exclusive distribution and licensing agreement with Dr. Reddy’s Laboratories...
